美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · PRAX近 30 天 1 則 · 第 1 / 1 頁
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Praxis (PRAX) Q2 2026 Earnings Call Transcript
- 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
- Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?
- Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary
- Praxis Precision Medicines Q2 Earnings Call Highlights
- Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ...
- Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath.
- These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months
- Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
- Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs
- Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
- Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
- Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation
- Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
- Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。